The Psychopharmacology of Alzheimer s Disease. Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school

Size: px
Start display at page:

Download "The Psychopharmacology of Alzheimer s Disease. Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school"

Transcription

1 The Psychopharmacology of Alzheimer s Disease Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school

2 Overview of Alzheimer s Disease Alzheimer s is a progressive degenerative disease Prevalence increases with age Annual cost is estimated at $100 billion dollars- 3 rd most costly disease in the U.S. Approximately 4 million Americans have AD 14 million will have Alzheimer s by 2050

3 Overview (cont) 1:10 over age 65 has AD Perhaps close to 1:2 has AD over age 85 50% of nursing home patients suffer from dementia Up to 50% of AD patients suffer from psychiatric complications

4 Clinical Presentation Checklist published by the Alzheimer s Association 1. Memory loss 2. Difficulty with familiar tasks 3. Language problems 4. Disorientation to time and place 5. Poor judgement

5 Clinical Presentation (cont) 6. Problems with abstract thinking 7. Misplacing things 8. Changes in mood and behavior 9. Changes in personality 10. Loss of initiative

6 Diagnosis Complete history, physical, lab panels Multiple sources of information Neuroimaging Neuropsycholgical battery Approximately 90% accuracy

7 Treatment of Behavioral Symptoms Whole variety of psychiatric symptoms are present in AD Depression, psychosis, anxiety, mania, aggression Multiple agents can abate these symptoms

8 Behavioral Symptoms (cont) Depression - usually seen in early AD - can be present at any time, but usually not full blown - psychotherapy maybe helpful early

9 Depression (cont) - trial of antidepressant is warranted - all equally efficacious, but side effects may differ - cost is also a factor - generic vs brand - compliance issues QD vs BID vs TID

10 Depression (cont) - TCAs e.g. Elavil, Tofranil are older dirtier drugs - should be avoided in AD patients - host of side effects including confusion, constipation, dizziness - unfortunately still prescribed for headache, pain syndromes, urinary incontinence

11 Depression (cont) SSRIs -1 st line agents in depressed AD patients - least toxic - more favorable side effect profile - Prozac, Zoloft,Paxil, Luvox, Celexa (recent FDA warning), Lexapro

12 Depression (cont) Other agents - Remeron - Effexor, Cymbalta - Wellbutrin - Viibryd - MAOIs such as Emsam - Stimulants e.g. Provigil, Ritalin

13 Behavioral Symptoms Psychosis - 30 to 50% of AD patients have psychotic symptoms - delusions or hallucinations - typically delusions of persecution and visual hallucinations

14 Psychosis (cont) -psychotherapy usually not helpful - antipsychotic medications are needed - multiple medications available - typical vs atypical - cost is a factor - side effects are a factor

15 Psychosis (cont) - typicals are older and less tolerable - examples include Haldol, Stelazine,Thorazine, Mellaril - side effects include sedation, confusion,and movement disorders - difficult to justify using these meds today

16 Psychosis (cont) - atypical or 2 nd generation agents are better tolerated, but not without their own side effects - Risperdal, Zyprexa, Seroquel,Geodon, Abilify, and Clozaril - most have been used successfully in this population - different formulations are available - FDA black box warning 2005

17 Behavioral Symptoms (cont) Mood lability - extremes in mood, highs and lows - possible mania - mood stabilizers are used including Depakote, Tegretol, and Lithium - atypical antipsychotics are also used

18 Behavioral Symptoms (cont) Agitation - encompasses combativeness, yelling, aggression - maybe present in 50% of AD patients - peaks in PM called sundowning - variety of behavioral and pharmacologic options available including Trazadone

19 Behavioral Symptoms (cont) Anxiety - should investigate if this is a premorbid trait - may use benzodiazepines, Buspar, Trazadone, Neurontin, atypical antipsychotics

20 Behavioral Symptoms (cont) Certain behaviors do not respond to pharmacologic treatment - wandering - disrobing - hoarding - sexualizing

21 Cognitive Symptoms These include amnesia, apraxia, agnosia, executive dysfunction Also included are functional symptoms such as ADLs and IADLs Behavioral symptoms may also overlap FDA approved AD treatments need to show cognitive efficacy

22 Cholinesterase Inhibitors These meds prevent breakdown of acetylcholine in the brain Acetylcholine deficits are seen in AD patients Acetylcholine probably plays a role in memory 4 FDA approved cholinesterase inhibitors

23 Cholinesterase Inhibitors (cont) Tacrine -1 st available CEI approved in fell out of favor because of hepatotoxicity, QID dosing, and frequent blood monitoring

24 Cholinesterase Inhibitors (cont) Donepezil (Aricept) - FDA approved in long t1/2 allows once daily dosing - side effects are usually GI in nature - can also see vivid dreams, sleep problems, and leg cramps - available as a generic

25 Cholinesterase Inhibitors (cont) Rivastigmine (Exelon) - FDA approved in 2000 for mild to moderate AD - may tend to cause more GI upset therefore need to titrate more slowly - BID dosing - also inhibits butyrylcholinesterase but benefit is unclear - Exelon patch better tolerated than capsules

26 Cholinesterase Inhibitors (cont) Galantamine (Reminyl) - FDA approved also acts as an allosteric modulator at nicotinic receptors - nicotine has shown effects in memory, attention, and learning in AD patients - BID dosed and needs to be titrated - available as generic

27 Cognitive Symptoms Memantine (Namenda) - NMDA receptor antagonist - approved for moderate to severe AD - patients required less caregiver time and showed a slower rate of decline - combination treatment may be better than monotherapy - well tolerated, BID dosed, could possibly use QD due to long t1/2

28 Memantine (cont) - mechanism is related to receptor overactivation by glutamate - this can lead to cell death and cognitive deficits - unclear if beneficial for mild to moderate patients; studies are ongoing - dose is 10mg bid

29 Cognitive Symptoms (cont) Vitamin E - an antioxidant which may slow progression of AD - Sano et al in NEJM 97 showed vitamin E to delay endpoints by 230 days - Morris et al found dietary but not supplemental vitamin E intake reduced risk of developing AD in patients - has fallen out of favor, possible cardiac toxicity

30 Cognitive Symptoms (cont) Estrogen - activates the cholinergic system - has antioxidant properties - women who were treated with estrogen postmenopause, were found to have decreased risk of developing AD - prospective studies have not shown supported this finding - treatment with estrogen may increase risk of heart disease and breast cancer

31 Cognitive Symptoms (cont) Ginkgo Biloba - an OTC anti-oxidant - LeBars et al showed modest improvement in patients taking ginkgo vs placebo - not FDA approved substance - need to watch for possible bleeding

32 Cognitive Symptoms (cont) Statins - lipid lowering agents widely used to decrease cholesterol - epidemiologic data suggest that increased cholesterol can increase risk of developing AD - one retrospective study showed patients treated with a statin had a 30% reduced risk of developing dementia - prospective studies are ongoing - may cause confusion in some

33 Cognitive Symptoms (cont) Homocysteine - an amino acid known as risk factor for cardiac disease - increased levels are associated with AD - folate, vitamin B12, and vitamin B6 will lower levels of homocysteine

34 Cognitive symptoms (cont) Clioquinol - a copper and zinc chelater that has shown benefit in mice models - iron, copper, and zinc may have role in AD pathogenesis - 36 AD patients at various stages had decrease in plasma AB - trials continue

35 Cognitive Symptoms (cont) Secretase Inhibitors - B-amyloid is formed from large Amyloid precursor protein (APP) - B-secretase and Gamma-secretase cleave APP into the toxic AB42 - therapies are being developed to inhibit actions of Beta and Gamma secretase - Gamma secretase inhibitors are in clinical trials

36 Summary AD at this point is still being treated symptomatically Treatments are available for both cognitive and noncognitive symptoms cocktail approach for treatment Patients may require polypharmacy There are approximately 70 new compounds in the Alzheimer s pipeline so we need to be patient

37 References 1.Samuels SC, Grossman H. Emerging Therapeutics for Alzheimer s Disease. CNS Spectrums 8: Farlow MR. Alzheimer s Treatment Update. CNS/Long Term Care Spring Sano,M. Noncholinergic Treatment Options for Alzheimer s Disease J Clin Psychiatry 64: Mintzer,J. The Search for Better Noncholinergic treatment Options for Alzheimer s Disease J Clin Psychiatry 64: Grossberg,G. Daignosis and Treatment of Alzheimer s Disease. J Clin Psychiatry 64:3-6

38 References (cont) 6.Sano,M. Current Concepts in the Prevention of Alzheimer s Disease. CNS Spectrums. 8: Jeste DV,Finkel SI. Psychosisof Alzheimer s Disease and Related Dis orders. Am J Geriatr Psychiatry 2000;8: LeBars PL, Katz MM, Berman N, A placebo-controlled, double-blind, randomized trial of an extract of ginkgo. JAMA. 1997;278: Leon J, Cheng C-K, Neumann,PJ. Alzheimer s disease care :costs and potential savings. Health Affairs 1998;17:

WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by

WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together Presented by Our agenda for today Understanding behavioral symptoms in people living with dementia Briefly review key strategies

More information

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

More information

Alzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,

Alzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, 2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,

More information

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer

More information

Pharmacy Drug Class Review

Pharmacy Drug Class Review April 16, 2010 Pharmacy Drug Class Review Disclaimer: Specific agents may have variations Dementia Review Focus on available treatments for Alzheimer s disease Authored By: Sarah Davis, Pharm.D Candidate

More information

Psychotropic Strategies Handout Package

Psychotropic Strategies Handout Package Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles

More information

2/12/2016. Drugs and Dementia in the Hospice Patient. Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources

2/12/2016. Drugs and Dementia in the Hospice Patient. Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources Drugs and Dementia in the Hospice Patient Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources 1 Drug Therapy: Targeted at Symptoms Cognitive: Impaired abstract thinking Impaired

More information

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY

More information

Primary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017

Primary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017 John Briles, MD, Medical Director October 11, 2017 Molina Healthcare of Michigan uses a HEDIS measure for Antidepressant Medication Management (AMM) to measure how well treating providers (PCPs) appropriately

More information

Diagnosis and Treatment of Alzhiemer s Disease

Diagnosis and Treatment of Alzhiemer s Disease Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised

More information

Alzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?

Alzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD? 2 Alzheimer s Disease Dementia is a brain disorder that seriously affects a person s ability to carry out daily activities. The most common form of dementia among older people is Alzheimer s disease (AD),

More information

Rational Medication Use in Dementia

Rational Medication Use in Dementia Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this

More information

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of

More information

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact

More information

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines

More information

Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.

Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease

More information

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally

More information

Caring for the Mind: Managing Depression and Anxiety. Highlights from 2017 ONS Congress

Caring for the Mind: Managing Depression and Anxiety. Highlights from 2017 ONS Congress Caring for the Mind: Managing Depression and Anxiety Highlights from 2017 ONS Congress Mood and Anxiety Disorders: Symptoms of mood disorders Non-reactive mood, worthlessness, guilt, loss of interest,

More information

Medication Treatments for Dementia. Stephen Thielke

Medication Treatments for Dementia. Stephen Thielke Medication Treatments for Dementia Stephen Thielke Treatment is a MORAL decision. Facts can help you determine HOW to accomplish something. Facts cannot tell you WHAT YOU WANT to accomplish. Dementia Meds

More information

Drugs for Emotional and Mood Disorders Chapter 16

Drugs for Emotional and Mood Disorders Chapter 16 Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,

More information

Michael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center

Michael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center Michael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center Dementia an acquired syndrome consisting of a decline in memory and other cognitive functions Alzheimer s Disease Fronto temporal

More information

Drug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle

Drug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Drug Update Treatments for Cognitive Impairment in the Older Adult William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Current Drug Treatments for Alzheimer s Disease Cholinesterase Inhibitors:

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

Reality, as perceived by the patient, constitutes the reality of the situation. My Mother s Doing What???!!

Reality, as perceived by the patient, constitutes the reality of the situation. My Mother s Doing What???!! My Mother s Doing What???!! Management & Treatment of Dementia Related Behaviors Objectives Describe the prevalence, etiology of dementia related behaviors that include physical outbursts & sexual hyperactivity.

More information

Medications for Alzheimer s disease: are they right for you?

Medications for Alzheimer s disease: are they right for you? Medications for Alzheimer s disease: are they right for you? There are no medications today that can cure Alzheimer s disease. But there are currently four medications approved by Health Canada which can

More information

Creating Partnerships. Laine Young-Walker, MD

Creating Partnerships. Laine Young-Walker, MD Creating Partnerships Laine Young-Walker, MD Psychiatry is the medical specialty devoted to the study, diagnosis, treatment and prevention of mental disorders. Medical school >>>four years of residency

More information

Significance A Busy Clinician's Guide to Seniors with Memory Loss

Significance A Busy Clinician's Guide to Seniors with Memory Loss Significance A Busy Clinician's Guide to Seniors with Memory Loss Victoria Braund MD FACP CMD Division of Geriatrics. NorthShore University HealthSystem Alzheimer's disease is the sixth leading cause of

More information

Dementia Pharmacotherapy

Dementia Pharmacotherapy Dementia Pharmacotherapy 1 early therapeutic interventions can maximize pharmacologic efficacy with these agents 2 Selecting a Medication Not enough evidence to recommend one agent over another based on

More information

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a

More information

A BRIEF LOOK AT DEMENTIA

A BRIEF LOOK AT DEMENTIA Dementia A BRIEF LOOK AT DEMENTIA David Kaufman, MD Neurology Consultants of Bellin Health November 2, 2017 Defined as a progressive decline in cognitive function that impairs daily activities. Always

More information

Alzheimer s disease. The facts in brief

Alzheimer s disease. The facts in brief Alzheimer s disease Dementia is an umbrella term used to describe various conditions which damage brain cells and lead to a loss of brain function over time. Dementia causes a progressive decline in a

More information

Alzheimer Disease and Related Dementias. Alzheimer Society of Manitoba Dr. David Strang

Alzheimer Disease and Related Dementias. Alzheimer Society of Manitoba Dr. David Strang Alzheimer Disease and Related Dementias Alzheimer Society of Manitoba Dr. David Strang What is Dementia? Dementia is a syndrome symptoms include loss of memory, judgment and reasoning, and changes in mood

More information

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder

More information

Outlines! Current Issue in Management. of Dementia! Cholinesterase Inhibitors! Medications that soon to be used in. Papan Thaipisuttikul, M.D.

Outlines! Current Issue in Management. of Dementia! Cholinesterase Inhibitors! Medications that soon to be used in. Papan Thaipisuttikul, M.D. Current Issue in Management of Dementia! Papan Thaipisuttikul, M.D. Department of Psychiatry Ramathibodi Hospital! Outlines! Current medications use in dementia management in Thailand. Medications that

More information

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine

More information

Contemporary Psychiatric-Mental Health Nursing. Psychopharmacology. Psychopharmacology - continued. Chapter 7 The Science of Psychopharmacology

Contemporary Psychiatric-Mental Health Nursing. Psychopharmacology. Psychopharmacology - continued. Chapter 7 The Science of Psychopharmacology Contemporary Psychiatric-Mental Health Nursing Chapter 7 The Science of Psychopharmacology Psychopharmacology A primary treatment mode of psychiatric-mental health nursing care Psychopharmacology - continued

More information

Behavioral Management in Dementia. a.k.a. Public Enemy Number One a.k.a. Proteins Gone Bad

Behavioral Management in Dementia. a.k.a. Public Enemy Number One a.k.a. Proteins Gone Bad Behavioral Management in Dementia a.k.a. Public Enemy Number One a.k.a. Proteins Gone Bad Game Plan 1. Definition 2. Epidemiology 3. Assessment: IT S OVER 4. Nonpharmacologic Strategies: 4 S 5. Nonpharmacologic:

More information

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP Dementia and Fall Geriatric Interprofessional Training Wael Hamade, MD, FAAFP Prevalence of Dementia Age range 65-74 5% % affected 75-84 15-25% 85 and older 36-50% 5.4 Million American have AD Dementia

More information

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018

Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.

More information

Current Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London

Current Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London Dementia Cognitive Non-cognitive (BPSD) Memory orientation language other cognitive abilities praxis planning

More information

BEYOND DEMENTIA: WHAT EVERYONE SHOULD KNOW ABOUT MENTAL HEALTH IN THE ELDERLY:

BEYOND DEMENTIA: WHAT EVERYONE SHOULD KNOW ABOUT MENTAL HEALTH IN THE ELDERLY: BEYOND DEMENTIA: WHAT EVERYONE SHOULD KNOW ABOUT MENTAL HEALTH IN THE ELDERLY: Beyond Managing Behavior Delivering Accurate & Effective Mental Healthcare MARSHALL, PARKER & WEBER, LLC 2016-20 TH ANNUAL

More information

Literature Scan: Alzheimer s Drugs

Literature Scan: Alzheimer s Drugs Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Presenter. Dr. Ronald Lucchino

Presenter. Dr. Ronald Lucchino Adverse Drug Reactions in Adults with Down Syndrome Presenter Dr. Ronald Lucchino rvluc@comcast.net PURPOSE To increase staff awareness that older adults with DD may have higher levels of medication in

More information

2015 Update on Psychotropics

2015 Update on Psychotropics 2015 Update on Psychotropics Jeffrey T. Apter, M.D. August 2015 Princeton Medical Institute 256 Bunn Drive, Suite 6, Princeton NJ (609) 921-6050 Learning Objectives Upon completion of this session, participants

More information

Fact Sheet Alzheimer s disease

Fact Sheet Alzheimer s disease What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,

More information

Behavior Problems: in Long Term Care and Assisted Living

Behavior Problems: in Long Term Care and Assisted Living Behavior Problems: Dementia and Mental Illness in Long Term Care and Assisted Living Module III Dr. David A. Smith, M.D., FAAFP, CMD mmlearn.org is a program of Morningside Ministries Cell Phones and Pagers

More information

Schedule FDA & literature based indications

Schedule FDA & literature based indications Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for

More information

We Will Discuss. Dementia and Alzheimer s Disease Basics. Dementia. Developmental Disabilities and Dementia: A Behavior Management Guide

We Will Discuss. Dementia and Alzheimer s Disease Basics. Dementia. Developmental Disabilities and Dementia: A Behavior Management Guide 10/18/2013 1 Dayna Thompson M.S., LMHC Alzheimer s Educator Developmental Disabilities and Dementia: A Behavior Management Guide Alzheimer s Resource Service IU Health Bloomington-Community Health 812-353-9299

More information

Medications and Children Disorders

Medications and Children Disorders Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for

More information

Psychiatric Medication Guide

Psychiatric Medication Guide Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants

More information

The Basics of Alzheimer s Disease

The Basics of Alzheimer s Disease 2017 Memory Loss Conference The Basics of Alzheimer s Disease Tom Ala, MD Center for Alzheimer s Disease and Related Disorders Southern Illinois University School of Medicine Springfield, Illinois SIU

More information

Are All Older Adults Depressed? Common Mental Health Disorders in Older Adults

Are All Older Adults Depressed? Common Mental Health Disorders in Older Adults Are All Older Adults Depressed? Common Mental Health Disorders in Older Adults Cherie Simpson, PhD, APRN, CNS-BC Myth vs Fact All old people get depressed. Depression in late life is more enduring and

More information

THE 3 D S OF GERIATRIC PSYCHIATRY: DEMENTIA & DELIRIUM MARK BOSMA MD FRCPC

THE 3 D S OF GERIATRIC PSYCHIATRY: DEMENTIA & DELIRIUM MARK BOSMA MD FRCPC THE 3 D S OF GERIATRIC PSYCHIATRY: DEPRESSION DEMENTIA & DELIRIUM MARK BOSMA MD FRCPC OBJECTIVES Differentiate between depression, dementia, and delirium Develop an approach to diagnosing the 3 D s Ds

More information

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free

More information

Dementia: Diagnosis and Treatment

Dementia: Diagnosis and Treatment Dementia: Diagnosis and Treatment Outline 1. Risk factors and definition of dementia 2. Types of Dementias 3. MMSE and testing 4. Treatment options Cognitive decline with aging Mild changes in memory and

More information

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics

Cognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also

More information

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be

More information

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty

More information

Guide to Psychiatric Medications for Children and Adolescents

Guide to Psychiatric Medications for Children and Adolescents Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists

More information

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2017. All rights reserved.

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information

Medication Treatment of Cognitive and Behavioral Symptoms in Dementia

Medication Treatment of Cognitive and Behavioral Symptoms in Dementia Medication Treatment of Cognitive and Behavioral Symptoms in Dementia Cary J. Kohlenberg, M.D. Medical Director, IPC Research and Independent Psychiatric Consultants Environmental interventions directly

More information

9/11/2012. Clare I. Hays, MD, CMD

9/11/2012. Clare I. Hays, MD, CMD Clare I. Hays, MD, CMD Review regulatory background for current CMS emphasis on antipsychotics Understand the risks and (limited) benefits of antipsychotic medications Review non-pharmacologic management

More information

BEHAVIORAL PROBLEMS IN DEMENTIA

BEHAVIORAL PROBLEMS IN DEMENTIA BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and

More information

Psychiatric Medications. Positive and negative effects in the classroom

Psychiatric Medications. Positive and negative effects in the classroom Psychiatric Medications Positive and negative effects in the classroom Teaching the Medicated Child Beverly Bryant, M.D. Hattiesburg Clinic 9/17/14 Introduction According to the National Survey of Children

More information

USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?

USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University

More information

Behavior Problems: Dementia and Mental Illness in Long Term Care and Assisted Living Module III

Behavior Problems: Dementia and Mental Illness in Long Term Care and Assisted Living Module III a program of Morningside Ministries Behavior Problems: Dementia and Mental Illness in Long Term Care and Assisted Living Module III Dr. David A. Smith, M.D., FAAFP, CMD Disclosures to Participants mmlearn.org

More information

Realities of Depression in Primary Care Setting

Realities of Depression in Primary Care Setting Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have

More information

Children s Hospital Of Wisconsin

Children s Hospital Of Wisconsin Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,

More information

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) 475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive

More information

The Confusion of Old Age: the relationship of dementia, depression, and agitation to executive dysfunction in the elderly

The Confusion of Old Age: the relationship of dementia, depression, and agitation to executive dysfunction in the elderly The Confusion of Old Age: the relationship of dementia, depression, and agitation to executive dysfunction in the elderly William B. Orr, Ph.D., M.D. Orr Memory William and B. Geriatric Orr, Ph.D., Behavioral

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

Understanding Alzheimer s Disease

Understanding Alzheimer s Disease Understanding Alzheimer s Disease Alzheimer s disease is an irreversible, progressive brain disorder that slowly impacts memory, thinking, skills and, eventually, the ability to carry out the simplest

More information

Understanding Dementia

Understanding Dementia Dementia Handbook for Carers Essex Understanding Dementia What is dementia? 1 Summary of dementia symptoms 4 Medication and treatment 5 1 Dementia is the name for several conditions that lead to the progressive

More information

PROJECTION: Worlds dementia population is expected to triple by 2050

PROJECTION: Worlds dementia population is expected to triple by 2050 DEMENTIA C L I S K C O N S U LTA N T P H Y S I C I A N I N A C U T E M E D I C I N E A N D G E R I AT R I C M E D I C I N E, B A R N E T H O S P I TA L, R O YA L F R E E N H S F O U N D AT I O N T R U

More information

OLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.

OLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia. Psychiatric disorders of the elderly OLD AGE PSYCHIATRY Dementia Depression Delusional disorder/late onset schizophrenia Delirium Dementia definition LOCALISATION OF CEREBRAL FUNCTION Impairment of multiple

More information

Neurocognitive Disorders Research to Emerging Therapies

Neurocognitive Disorders Research to Emerging Therapies Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia

More information

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17

More information

SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816

SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Managing Depression in Older Adults Developed March 1, 2003 Revised September 21,

More information

EARLY DEMENTIA. University of Hawaii Geriatric Medicine Department

EARLY DEMENTIA. University of Hawaii Geriatric Medicine Department EARLY DEMENTIA University of Hawaii Geriatric Medicine Department INTRODUCTION Dementia is very prevalent Screening and early diagnosis is important Evaluation Dementia Management DEMENTIA IS VERY PREVALENT

More information

Antipsychotics for Dementia Under Control or Over-Prescribed?

Antipsychotics for Dementia Under Control or Over-Prescribed? Antipsychotics for Dementia Under Control or Over-Prescribed? Nathaniel Hedrick, PharmD ProCare HospiceCare, Manager of Clinical Services Learning Objectives Summarize the disease progression and most

More information

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious

More information

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral

More information

Dementia care Update 2013/10/21. F/81 with Alzheimer s Disease

Dementia care Update 2013/10/21. F/81 with Alzheimer s Disease Dementia care Update Stanley KF Tam Executive council member, Coordinator of Education & Publication Subcommittee, Hong Kong Alzheimer s Disease Association Honorary Clinical Assistant Professor, Faculty

More information

Recognition and Management of Behavioral Disturbances in Dementia

Recognition and Management of Behavioral Disturbances in Dementia Recognition and Management of Behavioral Disturbances in Dementia Danielle Hansen, DO, MS (Med Ed), MHSA INTRODUCTION 80% 90% of patients with dementia develop at least one behavioral disturbances or psychotic

More information

Psychiatry curbside: Answers to a primary care doctor s top mental health questions

Psychiatry curbside: Answers to a primary care doctor s top mental health questions Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing

More information

Causes of Transient Incontinence. Geriatrics: Urinary Incontinence, Dementia, and Delirium. Classification of Established Incontinence

Causes of Transient Incontinence. Geriatrics: Urinary Incontinence, Dementia, and Delirium. Classification of Established Incontinence Causes of Transient Geriatrics: Urinary, Dementia, and Delirium Carla Zeilmann, PharmD, BCPS St. Louis College of Pharmacy Therapeutics 3 Fall 2003 D delirium I infection A atrophic urethritis and vaginitis

More information

Alzheimer s Dementia May 5, 2008

Alzheimer s Dementia May 5, 2008 Sharon Leigh, PharmD. BCPS Alzheimer s Dementia Page - 1 - I. Dementia vs. delirium Alzheimer s Dementia May 5, 2008 Dementia Gradual onset (insidious) Chronic illness progressing over years Irreversible

More information

Drugs 101: Behavioral Pharmacology

Drugs 101: Behavioral Pharmacology Drugs 101: Behavioral Pharmacology Eb Blakely, Ph.D., BCBA-D Quest, Inc./Florida Institute of Technology Drug Facts Drug effects are dose-dependent Drugs effects are time-dependent Drugs are toxic at high

More information

Cognitive disorders. Dr S. Mashaphu Department of Psychiatry

Cognitive disorders. Dr S. Mashaphu Department of Psychiatry Cognitive disorders Dr S. Mashaphu Department of Psychiatry Delirium Syndrome characterised by: Disturbance of consciousness Impaired attention Change in cognition Develops over hours-days Fluctuates during

More information

Medically Accepted Indications for Pediatric Use of Psychotropic Medications by

Medically Accepted Indications for Pediatric Use of Psychotropic Medications by Key: White Background: Medically Accepted Indication Yellow Backgroun: Medically Accepted Indication Status Not Ascertained Orange Background: Pediatric Indication cited, but not supported Red Background:

More information

A Primer on Psychotropic Medications. Michael Flaum, MD

A Primer on Psychotropic Medications. Michael Flaum, MD The Iowa Mental Health System and Employment for Individuals with Psychiatric Conditions Iowa Vocational Rehabilitation Services Conference Des Moines, IA, September 18, 2006 A Primer on Psychotropic Medications

More information

8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation

8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation Managing Psychiatric Conditions in Primary Care Beyond the Basics Source: US National Library of Medicine, Images from the History of Medicine Luis Berrios, DNP, MHA, ANP, PMHNP Internal Medicine & Primary

More information

Managing the Behavior Problems of Children With Fragile X Syndrome by Using Medication Ave M. Lachiewicz, MD, Duke University Medical Center

Managing the Behavior Problems of Children With Fragile X Syndrome by Using Medication Ave M. Lachiewicz, MD, Duke University Medical Center Managing the Behavior Problems of Children With Fragile X Syndrome by Using Medication Ave M. Lachiewicz, MD, Duke University Medical Center Abstract: The majority of boys and many girls with fragile X

More information

Mental Health Issues in Nursing Homes. I m glad you asked.

Mental Health Issues in Nursing Homes. I m glad you asked. Mental Health Issues in Nursing Homes I m glad you asked. I m glad you asked Susan Wehry, M.D. Associate Professor of Psychiatry, College of Medicine, University of Vermont Consultant, State of Vermont

More information

Medications, By Class, in TBI

Medications, By Class, in TBI Medications, By Class, in TBI Generic/Brand Name Drawback Advantage Mood Stabilizers (anti-seizure medications) Carbamazepine (Carbatrol ) (Equetro ) (Tegretol ) Gabapentin (Neurontin ) Lamotrigine (Lamictal

More information

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017 Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic

More information